The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living Individuals
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background and objectives: Hyperkalemia is associated with adverse outcomes in patients with CKD and in hospitalized patients with acute medical conditions. Little is known regarding hyperkalemia, cardiovascular disease (CVD), and mortality in community-living populations. In a pooled analysis of two large observational cohorts, we investigated associations between serum potassium concentrations and CVD events and mortality, and whether potassium-altering medications and eGFR<60 ml/min per 1.73 m 2 modified these associations. Design, setting, participants, & measurements: Among 9651 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS), who were free of CVD at baseline (2000–2002 in the MESA and 1989–1993 in the CHS), we investigated associations between serum potassium categories (<3.5, 3.5–3.9, 4.0–4.4, 4.5–4.9, and ≥5.0 mEq/L) and CVD events, mortality, and mortality subtypes (CVD versus non-CVD) using Cox proportional hazards models, adjusting for demographics, time-varying eGFR, traditional CVD risk factors, and use of potassium-altering medications. Results: Compared with serum potassium concentrations between 4.0 and 4.4 mEq/L, those with concentrations ≥5.0 mEq/L were at higher risk for all-cause mortality (hazard ratio, 1.41; 95% confidence interval, 1.12 to 1.76), CVD death (hazard ratio, 1.50; 95% confidence interval, 1.00 to 2.26), and non-CVD death (hazard ratio, 1.40; 95% confidence interval, 1.07 to 1.83) in fully adjusted models. Associations of serum potassium with these end points differed among diuretic users ( P interaction <0.02 for all), such that participants who had serum potassium ≥5.0 mEq/L and were concurrently using diuretics were at higher risk of each end point compared with those not using diuretics. Conclusions: Serum potassium concentration ≥5.0 mEq/L was associated with all-cause mortality, CVD death, and non-CVD death in community-living individuals; associations were stronger in diuretic users. Whether maintenance of potassium within the normal range may improve clinical outcomes requires future study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serum potassium should also be monitored in individuals treated with diuretics because these medications can cause hypokalemia, which is associated with cardiovascular risk and mortality (38)(39)(40).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
In the citing paper
“Serum potassium should also be monitored in individuals treated with diuretics because these medications can cause hypokalemia, which is associated with cardiovascular risk and mortality (38)(39)(40).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [38]
In the citing paper
“Restriction of dietary sodium (to <2,300 mg/day) may be useful to manage blood pressure and reduce cardiovascular risk (51,52), and individualization of potassium intake may be necessary to manage serum potassium concentrations (27,38,39).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [38]
In the citing paper
“Detection and management of these abnormalities is important because AKI and hyperkalemia each increase the risks of cardiovascular events and death (86).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [86]
In the citing paper
“Detection and management of these abnormalities is important because AKI and hyperkalemia each increase the risks of cardiovascular events and death (79).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [79]
Citations
Cites
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965 · cited 1×
“No adjustments were made for multiple comparisons, as our a priori hypothesis focused on these specific outcomes (19).”
BackgroundEstimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942 · cited 4×
“Participants in the CHS were all aged $65 years at baseline and there was no exclusion for prevalent CVD (7,8).”
BackgroundMethodInfluentialFlexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666 · cited 1×
“To examine the functional form of fully adjusted associations between unit change in serum potassium concentration with each outcome, we used penalized smoothing splines with evenly spaced knots among the inner 95% distribution (18).”
MethodThe Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652 · cited 1×
“Participants in the CHS were all aged $65 years at baseline and there was no exclusion for prevalent CVD (7,8).”
BackgroundSelf-citationApplying Cox Regression to Competing Risks
Lunn, M., & McNeil, D. (1995) · Biometrics · doi:10.2307/2532940 · Cited by 975 · cited 1×
“With regard to cause-specific mortality, we utilized competing risks models as described by Lunn and McNeil (17).”
MethodThe Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events
Bluemke, D. A., Kronmal, R. A., Lima, J. A. C., Liu, K., Olson, J., Burke, G. L., & Folsom, A. R. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.014 · Cited by 808 · cited 1×
“Total and CVD Mortality Total and CVD mortality were adjudicated by centralized events committees in both cohorts (11,12).”
MethodSurveillance and ascertainment of cardiovascular events
Ives, D. G., Fitzpatrick, A. L., Bild, D. E., Psaty, B. M., Kuller, L. H., Crowley, P. M., Cruise, R. G., & Theroux, S. (1995) · Annals of Epidemiology · doi:10.1016/1047-2797(94)00093-9 · Cited by 688
Self-citationLaboratory methods and quality assurance in the Cardiovascular Health Study
Cushman, M., Cornell, E. S., Howard, P. R., Bovill, E. G., & Tracy, R. P. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.2.264 · Cited by 439 · cited 1×
“In the CHS, serum potassium was measured in 5132 samples from the 1989–1990 and 1992–1993 exams at the University of Vermont Laboratory for Clinical Biochemistry Research following standard procedures for collection and storage, and using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, NY), a colorimetric m…”
MethodMeigs, J. B., Muller, D. C., Nathan, D. M., Blake, D. R., & Andres, R. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1475 · Cited by 338
Cited by
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
“Detection and management of these abnormalities is important because AKI and hyperkalemia each increase the risks of cardiovascular events and death (67).”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 485
“Detection and management of these abnormalities is important because AKI and hyperkalemia each increase the risks of cardiovascular events and death (39).”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
“kalemia each increase the risks of cardiovascular events and death (65).”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Collins, A. J., Pitt, B., Reaven, N., Funk, S., McGaughey, K., Wilson, D., & Bushinsky, D. A. (2017) · American Journal of Nephrology · doi:10.1159/000479802 · Cited by 403
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
Hyperkalemia: pathophysiology, risk factors and consequences
Hunter, R. W., & Bailey, M. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz206 · Cited by 253
“For example, in a racially diverse population of community-dwelling older adults, hyperkalemia was not associated with sudden cardiac death, whereas it was associated with death from cancer and other non-cardiac causes [60].”
Background11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Ohno, Y., Sone, M., Inagaki, N., Yamasaki, T., Ogawa, O., Takeda, Y., Kurihara, I., Itoh, H., Umakoshi, H., Tsuiki, M., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10263 · Cited by 198
Burrello, J., Monticone, S., Losano, I., Cavaglià, G., Buffolo, F., Tetti, M., Covella, M., Rabbia, F., Veglio, F., Pasini, B., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14063 · Cited by 167
“observed a high risk of adverse outcomes in patients with hypokalemia.(1,9,39)”
BackgroundPalmer, B. F. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.05.019 · Cited by 130
Hoppe, L. K., Muhlack, D. C., Köenig, W., Carr, P. R., Brenner, H., & Schöttker, B. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6783-0 · Cited by 105
Associations between serum potassium and adverse clinical outcomes: A systematic literature review
Palaka, E., Grandy, S., Darlington, O. T., McEwan, P. C., & van Doornewaard, A. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13421 · Cited by 65
Dietary potassium and the kidney: lifesaving physiology
Wei, K., Gritter, M., Vogt, L., de Borst, M. H., Rotmans, J. I., & Hoorn, E. J. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa157 · Cited by 61
Ambulatory Treatments for RAAS Inhibitor–Related Hyperkalemia and the 1-Year Risk of Recurrence
Hundemer, G. L., Talarico, R., Tangri, N., Leon, S. J., Bota, S. E., Rhodes, E., Knoll, G. A., & Sood, M. M. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12990820 · Cited by 49
Pun, P. H., Goldstein, B. A., Gallis, J. A., Middleton, J. P., & Svetkey, L. P. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.07.001 · Cited by 47
“0 mEq/l.(15) The relationship was not modified in interaction analyses based on eGFR levels.”
Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice
Nicola, L. D., Lullo, L. D., Paoletti, E., Cupisti, A., & Bianchi, S. (2018) · Journal of Nephrology · doi:10.1007/s40620-018-0502-6 · Cited by 58
“Hughes [9] General population 9651 80.”
Yalamanchili, H. B., Calp-Inal, S., Zhou, X. J., & Choudhury, D. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.07.014 · Cited by 45
“The risk of ESRD progression with low K can be debated, given discrepant findings from a prospective observational study and a large retrospective observational study.(35,37) In summary, hypokalemic nephropathy is a potential complication of subacute and chronic low K (Table 3).”
BackgroundProvenzano, M., Minutolo, R., Chiodini, P., Bellizzi, V., Nappi, F., Russo, D., Borrelli, S., Garofalo, C., Iodice, C., Stefano, T. D., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120499 · Cited by 45
Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1
Takeda, Y., Demura, M., Kometani, M., Karashima, S., Yoneda, T., & Takeda, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065782 · Cited by 42
Johnson, L., Mattsson, N., Sajadieh, A., Wollmer, P., & Söderholm, M. (2017) · Stroke · doi:10.1161/strokeaha.117.018148 · Cited by 40
Fan, Y., Wu, M., Li, X., Zhao, J., Shi, J., Ding, L., Jiang, H. F., Li, Z., Zhang, W., Ma, T., et al. (2024) · Nutrition Journal · doi:10.1186/s12937-023-00888-z · Cited by 46
“The health hazards associated with dyskalemia have been extensively investigated in the general population, suggesting that abnormal potassium levels increase the risk of cardiometabolic diseases and mortality [9–11].”
BackgroundRegulation of Potassium Homeostasis in CKD
DuBose, T. D. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.06.002 · Cited by 42
Nabrdalik, K., Kwiendacz, H., Drożdż, K., Irlik, K., Hendel, M., Wijata, A. M., Nalepa, J., Correa, E. S., Hajzler, W., Janota, O., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101694 · Cited by 39
Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa133 · Cited by 31
Impact of age on extracorporeal membrane oxygenation survival of patients with cardiac failure
Lee, S. N., Jo, M. S., & Yoo, K. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s142994 · Cited by 28
“Moreover, hyperkalemia is associated with cardiovascular events and mortality.(24) Usually, younger patients have more muscle mass than older patients.”
Pro: The rationale for dietary therapy for patients with advanced chronic kidney disease
Kopple, J. D., & Fouque, D. P. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx333 · Cited by 31
Sriperumbuduri, S., McArthur, E., Hundemer, G. L., Canney, M., Tangri, N., Leon, S. J., Bota, S., Bugeja, A. L., Akbari, A., Knoll, G. A., et al. (2021) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581211017408 · Cited by 20
Treatment of Abnormalities of Potassium Homeostasis in CKD
Palmer, B. F., & Clegg, D. J. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.06.001 · Cited by 19
Jiménez‐Marrero, S., Cainzos‐Achirica, M., Monterde, D., García‐Eroles, L., Enjuanes, C., Yun, S., Garay, A., Moliner, P., Alcoberro, L., Corbella, X., et al. (2020) · Clinical Epidemiology · doi:10.2147/clep.s253745 · Cited by 18
Serum Potassium and Cardiovascular Outcomes: The Highs and the Lows
Toto, R. D. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00030117 · Cited by 16
Kashihara, N., Nishio, T., Osonoi, T., Saka, Y., Imasawa, T., Ohtake, T., Mizuno, H., Shibagaki, Y., Kim, H., Yajima, T., et al. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01937-1 · Cited by 16
Brookes, E. M., Snider, J., Hart, G. K., Robbins, R., & Power, D. A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14970 · Cited by 13
Intracellular chloride: a regulator of transepithelial transport in the distal nephron
Rodan, A. R. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000502 · Cited by 14
Liu, S., Zhao, D. H., Wang, M., Qi, Y., Sun, J., Liu, J., Liu, J., & Liu, J. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07111-x · Cited by 13
Reverse pseudohyperkalemia is more than leukocytosis: a retrospective study
Shamy, O. E., Rein, J. L., Kattamanchi, S., Uribarri, J., & Vassalotti, J. A. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa144 · Cited by 11
Du, X., Wang, R., Zhai, J., & Xie, X. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04301-2 · Cited by 10
Huang, W., Zhu, J., Song, C., & Lu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-51468-y · Cited by 10
The Guidelines for use and promotion of low sodium salt in China
Yuan, Y., Gao, C., Yin, X., Zhang, X., Ji, Y., Zheng, X., Zhou, Q. X., & Wu, Y. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12621 · Cited by 10
Delving into biomarkers and predictive modeling for CVD mortality: a 20-year cohort study
Wu, Z., Hilowle, A. A., Ying, Z., Zhao, C., & Yang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-88790-y · Cited by 12
Jiménez‐Marrero, S., Cainzos‐Achirica, M., Monterde, D., Vela, E., Clèries, M., García‐Eroles, L., Enjuanes, C., Yun, S., Garay, A., Moliner, P., et al. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.06.013 · Cited by 9
Jiménez‐Marrero, S., Cainzos‐Achirica, M., Monterde, D., Vela, E., Clèries, M., García‐Eroles, L., Enjuanes, C., Yun, S., Garay, A., Moliner, P., et al. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.06.016 · Cited by 9
Fasting serum potassium and long-term mortality in healthy men
Falk, R. S., Robsahm, T. E., Paulsen, J. E., Stocks, T., Drake, I., & Heir, T. (2021) · BMC Public Health · doi:10.1186/s12889-021-10738-4 · Cited by 8
“Regarding all-cause mortality, conflicting results have been reported, with a linear association [7, 9, 15], a Ushaped association [10, 16], association only for high potassium levels [5, 6], and no association [11] has been observed.”
BackgroundResultObi, Y., Thomas, F., Dashputre, A. A., Goedecke, P. J., & Kovesdy, C. P. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100757 · Cited by 7
Effect of potassium on DNA methylation of aldosterone synthase gene
Takeda, Y., Demura, M., Wang, F., Karashima, S., Yoneda, T., Kometani, M., Aomo, D., Hashimoto, A., Horike, S., Meguro‐Horike, M., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002742 · Cited by 7
Dashputre, A. A., Sumida, K., Potukuchi, P. K., Kar, S., Obi, Y., Thomas, F., Molnar, M. Z., Streja, E., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000514294 · Cited by 6
Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease
Caravaca‐Fontán, F., Valladares, J., Díaz-Campillejo, R., Barroso, S., Luna, E., & Caravaca, F. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2019.10.001 · Cited by 6
Romero-González, G. A., Bover, J., Arrieta, J., Salera, D., Troya, M. I., Graterol, F., Ureña, P., Cozzolino, M. G., Lullo, L. D., Cippà, P. E., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11143970 · Cited by 4
Lizama, P. M., Ríos, D. L., Cachinero, I. S., Toloba, A., Camps, A., Belzares, O., Pacheco, C., Cerro, C., Wehinger, S., Fuentes, E., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080722 · Cited by 4
“0 mEq/L) has been associated with cardiovascular mortality, especially in diuretic users [35], and it has been suggested that early detection and treatment of hyperkalemia may reduce the risk of sudden cardiac death in patients with CKD [36].”
BackgroundThe Importance of a “Just Right” Serum Potassium Level
Mehta, A. N., & Emmett, M. (2017) · American Journal of Nephrology · doi:10.1159/000479803 · Cited by 4
Pathophysiology and clinical management of hyperkalemia in chronic kidney disease
Palmer, B. F., & Clegg, D. J. (2023) · Minerva Medica · doi:10.23736/s0026-4806.23.08465-3 · Cited by 3
Asociación entre hiperkaliemia y evolución clínica en la enfermedad renal crónica avanzada
Caravaca‐Fontán, F., Valladares, J., Díaz-Campillejo, R., Barroso, S., Luna, E., & Caravaca, F. (2019) · Nefrología · doi:10.1016/j.nefro.2019.01.007 · Cited by 3
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
“Individuals taking diuretics should also have their serum potassium levels checked since these drugs can produce hypokalemia, which is linked to an increased risk of heart disease and death [40]-[42].”
Ke, B., Shen, A., Qiu, H., Li, W., Chen, H., & Li, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1216422 · Cited by 2
“incidents of adverse cerebrovascular events (12, 13).”
Klemm, J., Shariat, S. F., Laukhtina, E., Rajwa, P., Vetterlein, M. W., Schuettfort, V. M., von Deimling, M., Dahlem, R., Fisch, M. M., & Rink, M. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102079 · Cited by 2
Abdollahi-Karizno, M., Partovi, N., Noferesti, V., Ravanbakhsh, N., Kazemi, T., & Bizhaem, S. K. (2021) · PubMed Central · doi:10.22122/arya.v17i0.2149 · Cited by 2
Nephrologische Therapie der schweren Herzinsuffizienz
Schwenger, V., & Remppis, B. A. (2018) · Der Nephrologe · doi:10.1007/s11560-017-0223-1 · Cited by 2
Outcomes Associated With Potassium Abnormalities in CKD: It Is Time to Move to Clinical Trials
Kovesdy, C. P. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.05.002 · Cited by 2
Potassium Metabolism in Chronic Kidney Disease
Palmer, B. F., & Clegg, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00040-1 · Cited by 1
López‐López, A., Regueiro‐Abel, M., Paredes-Galán, E., Johk-Casas, C. A., Viéitez-Flórez, J. M., Elices‐Teja, J., Rivas, J. A., Franco‐Gutiérrez, R., Ríos-Vázquez, R., & González‐Juanatey, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010058 · Cited by 1
Nguyen, T. P. P., Hennessy, S., Brensinger, C. M., Bilker, W. B., Dember, L. M., Miano, T. A., Vo, T., Willis, A. W., & Leonard, C. E. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70584 · Cited by 1
“33,34 Clinical guidelines have suggested that serum potassium levels have a U-shaped relationship with mortality in individuals with HF, such that both hypokalaemia and hyperkalaemia are associated with higher risk.”
(2019) · Internal Medicine Research – Open Journal · doi:10.31038/imroj.2019411
Modification of Potassium-Mortality Relationship by Ethnicity and Race: Solving the Puzzle
Agarwal, R. (2017) · American Journal of Nephrology · doi:10.1159/000476004 · Cited by 1
Potasio, la estrecha franja entre la vida y la muerte
Galcerán, J. (2017) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2017.06.002
Гиперкалиемия и хроническая болезнь почек
Kushnirenko, S. V. (2021) · KIDNEYS · doi:10.22141/2307-1257.8.1.2019.157791
Mathew, R. O., Fernandes, V. L. C., & Bangalore, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-45414-2_10
Ambruso, S. L. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.03.895
“Although Hughes-Austin et al.2 described increased cardiovascular events and mortality risk with even small increases in serum potassium in community-living 1203 individuals in 2017, the cohort was relatively small.”
BackgroundInjeti, N. (2021) · International Journal of Clinical Pharmacokinetics and Medical Sciences · doi:10.26452/ijcpms.v1i4.199
Li, G., Li, J., & Le, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2254716/v1
Profile of Potassium Serum in Coronary Heart Disease (CHD)
Rosita, L., & Kasyiva, M. (2022) · doi:10.2991/978-94-6463-048-0_12
Li, J., & Li, G. (2022) · Research Square · doi:10.21203/rs.3.rs-2357963/v1
Garzaro, J. R. R., Godoy, J. J. G., & Fuentes, Á. P. (2022) · Revista de la Facultad de Medicina · doi:10.37345/23045329.v1i33.88 · Cited by 2
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Fan, Y., Wu, M., Li, X., Zhao, J., Shi, J., Ding, L., Jiang, H., Li, Z., Zhang, W., Ma, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26665915
Fan, Y., Wu, M., Li, X., Zhao, J., Shi, J., Ding, L., Jiang, H., Li, Z., Zhang, W., Ma, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26665918
Zhang, H., He, F., Fang, Z., Zheng, G., Zhou, B., Chen, X., Liu, M., & Hao, G. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70041
“It has been reported that elevated serum potassium levels increase the risk of ventricular arrhythmias in patients with acute myocardial infarction, suggesting a potential mechanistic explanation for the association of elevated serum potassium levels with all‐cause mortality [31].”
A Life-Threatening Paradox in Managing a Case of Severe Hypokalemia
Mudarres, M. F., & Cheng, C. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100089
Development of a nomogram for predicting hyperkalemia in advanced chronic kidney disease
Chavez-Iñiguez, J. S., Ornelas-Ruvalcaba, R. L., Rodríguez-García, G., Navarro‐Blackaller, G., Medina-González, R., Gallardo-González, A. M., Alcantar-Vallin, L., Abundis-Mora, G. J., Gómez-Fregoso, J. A., García-García, G., et al. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2709935
“HyperK exerts a profound clinical impact [10].”
Diagnosis and management of acute hyperkalaemia
Rech, M. A., Zimmerman, D. E., Ray, L. C., Desai, D., Hoffman, J. W., & Howington, G. T. (2026) · BMJ · doi:10.1136/bmj-2026-100287 · Cited by 1
O’Brien, J., Patel, M. J., & Schrock, J. W. (2026) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2026.09.028
Metadata
- Authors
- Hughes-Austin, J. M., Rifkin, D. E., Beben, T., Katz, R., Sarnak, M. J., Deo, R., Hoofnagle, A. N., Homma, S., Siscovick, D. S., Sotoodehnia, N., Psaty, B. M., de Boer, I. H., Kestenbaum, B., Shlipak, M. G., & Ix, J. H.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-01-31
- Volume
- 12
- Issue
- 2
- Pages
- 245-252
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5293337
- OpenAlex
- W2585143408
- Semantic Scholar
- b2fb70503ddc38b38f8e2fbfeae067172e33e713
- Cited by
- 92
- References
- 25
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 8 · 2022: 8 · 2021: 12 · 2020: 12 · 2019: 11 · 2018: 9 · 2017: 12
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01hc085082-026, n01hc085081-021, n01hc085079-024, n01hc085083-027, n01hc085080-026, n01hc095169-003, n01hc085086-022, n01hc55222-0-0-0, n01hc95159-40-0-1)
- National Institute on Aging (R01AG023629)
- National Heart, Lung, and Blood Institute (N01 HC085086, R01HL096875, N01-HC095169, N01 HC085079, N01 HC085083, N01 HC085080, HHSN 268200800007C, N01-HC-095159, K01HL122394, R01HL102214, HHSN268201200036C, N01HC085082, U01HL080295, N01 HC055222, N01 HC085081, R01HL080295)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK098234, K23DK091521)
- Topics
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- hyperkalemia, serum potassium, cardiovascular events, all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, diuretics, estimated glomerular filtration rate, community-dwelling adults, Multi-Ethnic Study of Atherosclerosis, Cardiovascular Health Study, CKD-mineral and bone disorder, potassium-sparing diuretics
- MeSH terms
- Aged, Cardiovascular Diseases, Cause of Death, Diuretics, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hyperkalemia, Male, Middle Aged, Potassium, United States, Independent Living, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.